Aerie Pharmaceuticals Stock Total Debt
| AERIDelisted Stock | USD 15.25 0.01 0.07% |
Aerie Pharmaceuticals fundamentals help investors to digest information that contributes to Aerie Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Aerie Stock. The fundamental analysis module provides a way to measure Aerie Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aerie Pharmaceuticals stock.
Aerie |
Aerie Pharmaceuticals Company Total Debt Analysis
Aerie Pharmaceuticals' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Aerie Pharmaceuticals Total Debt | 234.53 M |
Most of Aerie Pharmaceuticals' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aerie Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
CompetitionBased on the latest financial disclosure, Aerie Pharmaceuticals has a Total Debt of 234.53 M. This is 91.48% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The total debt for all United States stocks is 95.59% higher than that of the company.
Aerie Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aerie Pharmaceuticals' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aerie Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aerie Pharmaceuticals by comparing valuation metrics of similar companies.Aerie Pharmaceuticals is currently under evaluation in total debt category among its peers.
Aerie Fundamentals
| Return On Equity | -22.55 | |||
| Return On Asset | -0.0459 | |||
| Profit Margin | (0.17) % | |||
| Operating Margin | (0.12) % | |||
| Current Valuation | 918.14 M | |||
| Shares Outstanding | 49.42 M | |||
| Shares Owned By Insiders | 1.79 % | |||
| Shares Owned By Institutions | 98.21 % | |||
| Number Of Shares Shorted | 1.52 M | |||
| Price To Earning | (19.00) X | |||
| Price To Book | 34.26 X | |||
| Price To Sales | 3.52 X | |||
| Revenue | 194.13 M | |||
| Gross Profit | 167.29 M | |||
| EBITDA | (7.81 M) | |||
| Net Income | (74.81 M) | |||
| Cash And Equivalents | 184.37 M | |||
| Cash Per Share | 3.73 X | |||
| Total Debt | 234.53 M | |||
| Debt To Equity | 9.41 % | |||
| Current Ratio | 2.60 X | |||
| Book Value Per Share | 0.51 X | |||
| Cash Flow From Operations | (99.15 M) | |||
| Short Ratio | 1.91 X | |||
| Earnings Per Share | (1.47) X | |||
| Target Price | 15.35 | |||
| Number Of Employees | 376 | |||
| Beta | -0.062 | |||
| Market Capitalization | 753.62 M | |||
| Total Asset | 431.39 M | |||
| Retained Earnings | (919.58 M) | |||
| Working Capital | 121.31 M | |||
| Current Asset | 138.43 M | |||
| Current Liabilities | 17.12 M | |||
| Z Score | -4.8 | |||
| Net Asset | 431.39 M |
About Aerie Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aerie Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aerie Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aerie Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Aerie Stock
If you are still planning to invest in Aerie Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aerie Pharmaceuticals' history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |